A carregar...
Phase I and pharmacokinetic study of everolimus, an mTOR inhibitor, in combination with docetaxel for recurrent/refractory non-small cell lung cancer
PURPOSE: Everolimus is a novel inhibitor of the mammalian target of rapamycin (mTOR) pathway, which is aberrantly activated in non-small cell lung cancer (NSCLC). We conducted a phase I and pharmacokinetic study of everolimus and docetaxel for recurrent NSCLC. METHODS: Patients with advanced stage N...
Na minha lista:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2010
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2940062/ https://ncbi.nlm.nih.gov/pubmed/20564143 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.25264 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|